About

About Genomeditech Genomeditech (Shanghai) Co., Ltd. was established in 2011 and is a high-tech enterprise specializing in the research and development of cutting-edge biotechnology. We have established technology platforms in molecular biology, cell biology, virus packaging, cell line construction, reporter genes, antibody expression, protein expression, and IVD. In 2020, Genomeditech launched a sub-brand, DDXCELL, focusing on biopharmaceutical development by providing efficient R&D tools and solutions. As of now, the company has developed nearly 400 popular drug targets and over 1,000 available monoclonal cell lines. These targets include tumor-associated antigens (TAA), immune checkpoints, cytokines, kinases, and more. Additionally, a large collection of proteins, antibodies, and reagents is available. To support vaccine development, Genomeditech has also introduced a series of ready-to-use pseudoviruses and receptor cells, covering products for COVID-19, influenza, HPV, and other pathogens.